A cytolytic T lymphocyte (CTL) clone that lyses many HLA-A2 melanomas was derived from a population of tumor-infiltrating lymphocytes of an HLA-A2 melanoma patient. The gene coding for the antigen recognized by this CTL was identified by transfection of a cDNA library. It is the gene which has been reported to code for N-acetylglucosaminyltransferase V (GnT-V). Remarkably, the antigenic peptide recognized by the CTL is encoded by a sequence located in an intron. In contrast to the fully spliced GnT-V mRNA, which was found in a wide range of normal and tumoral tissues, the mRNA containing the intron region coding for the antigen was not found at a significant level in normal tissues. This mRNA was observed to be present in about 50% of melanomas. Our results suggest that a promoter located near the end of the relevant intron is activated in melanoma cells, resulting in the production of an mRNA coding for the antigen.
C
Ytolytic T lymphocytes (CTL) directed against human tumor cells have been obtained by culture of irradiated tumor cells with autologous blood lymphocytes, or with tumor infiltrating lymphocytes (reviewed in reference 1). From these responder T cell populations, it has been possible to derive stable anti-tumor CTL clones that do not lyse autologous fibroblasts, EBV-transformed autologous B cells, or target cells that are lysed by NK-like effectors (2) (3) (4) (5) (6) .
Two main categories of antigens recognized on human melanomas by autologous CTL have been described so far. Some antigens are encoded by genes that are expressed in a wide range of tumors of different histological types but not in normal tissues except in testis and placenta. Examples are the MAGE gene family (7, 8) , the BAGE gene (9) , and the GAGE gene family (10) . Others are differentiation antigens encoded by genes that are expressed only in melanocytes and in melanomas, such as those encoded by tyrosinase (11) (12) (13) (14) and those encoded by Melan-A ~a~T-I (15, 16) gpl0O Pme117 (17, 18) , and gp75 Tp'PI (19) .
We report here the identification of another gene coding for a melanoma antigen, which is recognized by a CTL clone on a majority of HLA-A2 melanomas. The antigenic peptide which binds to HLA-A2.1 is encoded by an intron sequence of the gene that codes for N-acetylglucosaminyltransferase V.
Material and Methods
Cell Lines. Tumor ceU lines NA8-MEL, NA17-MEL, and NA74-MEL were derived from the metastatic melanomas of patients NA8, NA17, and NA74. Cell line MZ2-MEL is a subclone of the original MZ2-MEL melanoma line, and was described previously as MZ2-MEL.43 (5, 20) . This subclone expresses tyrosinase. Subline MZ2-MEL.2.2.5, used for construction of the genomic library, was derived as described (10) . Melanoma cell fines SK29-MEL and SY, L23-MEL, and RNA extracted from cultivated melanocytes were gifts from Dr. L. Old (Memorial Sloan-Kettering Cancer Center, New York). Tumor cell fines LB373-MEL and LB168-MEL were derived from melanoma patients LB373 and LB168 respectively. Tumor cell lines MI10221 and 526-mel were kindly provided by Dr. G. Parmiani (Istituto Nazionale Tumoil, Milan, Italy) and Dr. S.A. Rosenberg (National Cancer Institute, Bethesda, MD), respectively. CTL clone NA17-CTL-213, referred to as CTL 213, was derived from TIL of patient NA17 (6) . Lymphoblastoid cells NA17-EBV were derived from patient NA17 by standard techniques.
Assay for Cytolytic Activity. The chromium release assay was performed as described elsewhere (5) . Briefly, 1,000 51Cr-labeled target cells were incubated with CTL 213 at different effectorto-target ratios. Chromium release in the supernatant was measured after 4 h of incubation.
Construction of the eDNA Library. Poly-A*(RNA) was obtained from MZ2-MEL cells using the Fastrack mRNA extraction kit ([nvitrogen Corporation, Oxon, UK). mRNA was converted to cDNA using an oligo-dT(Notl, EcoRl) primer. The cDNA was ligated to BstXl adaptors, digested with NotI and inserted into the BstXl and Notl sites of expression vector pcDNAI/Amp (Invitrogen Corporation, Oxon, UK). Recombinant plasnfids were electroporated into DH5~x Escherichia coil bacteria and selected with ampicillin (50 p~g/ml). Bacteria were amplified to saturation and plasnfid DNA was extracted by the alkahne lysis method (21) .
Transfection of COS-7 Cells. Transfection experiments were
performed by the DEAE-dextran-chloroquine method (11, 15, 22) . Briefly 1.5 • 104 COS-7 cells were treated with 100 ng of plasmid pcDNAI/Amp-A2, a recombinant plasmid containing the HLA-A2.1 gene isolated from a CTL clone of patient SK29 (23) , and 100 ng ofDNA of a pool of the cDNA library. Transfected COS-7 cells were tested in a CTL stimulation assay after 48 h.
CTL Stimulation Assay.
Transfectants were tested for their ability to stimulate the production of Tumor Necrosis Factor (TNF) by CTL (24) . Briefly, in microwells containing target cells, 2,500 CTL were added in 100 ILl of RPMI 1640 medium (Gibco BRL, Gaithersburg, MD) containing 10% human serum and 25 U/ml r-hu-lL2. After 48 h, the supernatant was collected and its TNF content was determined by testing its cytotoxic effect on WEHI-164 clone 13 cells (25) in a MTT colorimetric assay (24, 26) .
DNA Sequencing and Homology
Search. DNA sequencing analysis was performed by specific priming with synthetic oligonucleotides. The sequencing reactions were performed by the dideoxychain termination method (T7 Sequencing Kit; Pharmacia, Uppsala, Sweden, ATaq TM Cycle-Sequencing Kit; USB, Cleveland, OH). The computer search for sequence homology was done with the blast program.
Production of Fragments of cDNA 560
Prqc~ressive Deletions in eDNA 560. Screening of the Genomic Library. A genomic library of 1.1 • 106 independent X phages was constructed with DNA from MZ2-MEL2.2.5 by standard techniques (21) . A labeled cDNA 560 fragment (nt 47 to 185) was used as a probe (probe B) for colony hybridization. A positive phage was isolated and digested with Sacl. The fragments were size-fractionated in a 0.7% agarose gel and blotted on a nitrocellulose filter. The filter was hybridized with probe A, a 33p-labeled oligonucleotide (5'-GGTTTCTC-GAAGAAGGAACTGC-3') specific of exon "'A" of GnT-V cDNA (positions 1651 to 1672). 5.5-and 8.5-kb fragments, hybridizing with probe A and probe B, respectively, were then subcloned in plasmid pTZ19R (Pharmacia Fine Chemicals, Piscataway, NJ) and partially sequenced.
mRNA Analysis. Anchored PCR amplifications of 5' and 3' ends of the cDNA coding for NA17-A antigen were performed. cDNA was synthesized using total RNA from HLA-A2 melanoma cell line LB24-MEL as template.
5" End Amplification. 5 31End Amplification. The primer used for cDNA synthesis was EDP1260 (5'-GACTCGAGTCGACATCGATTTTTT-TTTTTTTTTTT-3', described by Frohman [27] ). A first PCR amplification was done with sense primer VB72 (5'-ATGGTC-CTGCCTGATGTG-3') and anti-sense primer EDP1260. A second PCR amplification was done with sense primer VB45 (5'-GATGTGTTCATACGCTGTGTGGT-3') and anti-sense primer EDP1260. The amplified product was cloned as above.
In Vitro Transcription Assay. Antigenic Peptides and CTL Assay. Peptides were synthesized on solid phase using F-moc for transient NH2-terminal protection as described (28) and characterized by mass spectrometry. All peptides were >90% pure as indicated by analytical HPLC. Lyophilized peptides were dissolved in DMSO and stored at -80~ They were tested by chromium release assay as previously de-scribed (29) . In this peptide sensitization assay, target cells were SlCr-labeled for one hour at 37~ and washed extensively. 1,000 target cells were then incubated in 96-well microplates in the presence of various concentrations ofpeptides for 30 min at 37~ and CTL 213 (10,000 cells) were added. Chromium release was measured after 4 h at 37~
RT-PCR Assays. Total RNA was extracted by the guanidine-isothiocyanate procedure as described (30) . For amplification of NA17-A cDNA (PCtk "I-C"), VB45 was used as sense primer (primer i) and (5'-CTCTACTTCCTCC-TGATTGTTGAG-3') as anti-sense primer (primer c). For amplification of GnT-V cDNA (PCR "A-B"), primer a (5'-GAT-CTACTTGGACATTATTCACAC-3') was used as sense primer and primer b (5'-CATCCATTTGCGATAGCTTCCAG-3') as anti-sense primer. For amplification of cDNA 560, VB45 was used as sense primer, and SL6 (5'-CAATGTCGGTCTTTTCT-GTC-3') as anti-sense primer. The ability ofoligonucleotide SL6 to prime DNA synthesis in presence of template cDNA was tested with sense primer SL5 (5'-GAAGAAGAGCAGGTCA-GCAGTC-3'), located in positions 345 to 366 of cDNA 560. This control reaction yielded specific amplification products with several tumoral R.NAs.
PCR. were performed for 30 cycles (1 rain at 94~ 2 rain at 62~ and 2 min at 72~ 10 ~1 of the PCR product were fractionated on a 1.5% agarose gel. The quality of RNA preparations was checked by PCtk amplification of ~-actin cDNA with primers (5'-GGCATCGTGATGGACTCCG-3') and (5'-GTCG-GAAGGTGGACAGCGA-3') for 21 cycles of 1 rain at 94~ 2 rain at 65 ~ and 2 min at 72~ PCR assays for tyrosinase expression were performed as described (11), except that the number of cycles varied between 30 and 38 cycles.
For quantitative expression measurements, cDNA was synthesized as above. R.NA obtained from MZ2-MEL cells was used undiluted or serially diluted in E. coli tRNA for each series of quantitative PCR. 0.2 ~xCi of labeled dCTP (3,000 Ci/mmol) were added to the PCR mix. The number of cycles was reduced to 24 for PCtk I-C, to 25 for PCP,. A-B and to 18 for ~-actin PCR so that a linear dilution curve of the standard was obtained. Accurate quantitation was obtained using the phosphor-imager technology (Phosphor-Imager; Molecular Dynamics, Sunnyvale, CA).
Results

An Anti-melanoma CTL clone Restricted by HLA-A2. I.
Melanoma cell line NA17-MEL was estabhshed from a cutaneous metastasis of patient NA17. Anti-tumor CTL were obtained from tumor-infiltrating lymphocytes by culturing fragments of a metastasis in presence of IL-2 (6) . This CTL population was restimulated with irradiated NA17-MEL cells under limiting dilution conditions, and stable antitumor CTL clones were obtained (6) .
CTL clone NA17-CTL-213, further referred to as CTL 213, lysed the autologous melanoma cell line but lysed neither K562 nor autologous EBV-transformed B cells (Fig.  1) . The target antigen of this CTL was named NA17-A. CTL clone 213 lysed 12 other melanoma cell lines carrying the HLA-A2 haplotype among the 15 that were tested, suggesting that antigen NA17-A is presented by HLA-A2 (31) . It also produced TNF in the presence of NA17-MEL and other HLA-A2 melanoma cell lines (Fig. 2) .
The lysis inhibition observed with two distinct anti-HLA-A2 monoclonal antibodies confirmed that HLA-A2 was the presenting molecule for the antigen recognized by CTL 213 (31) . This was confirmed further by transfection of the HLA-A2.1 gene into melanoma line MZ2-MEL, which does not carry the HLA-A2 gene. The acquisition of the HLA-A2.1 sequence rendered this cell line capable of stimulating TNF release by CTL 213 (Fig. 2) .
A cDNA Coding for Antigen NA 17oA. A cDNA library was constructed in expression vector pcDNAI/Amp with poly A + (RNA) extracted from MZ2-MEL cells. The library was divided into 640 pools containing each '~90 bacteria carrying an insert. Plasmid DNA of each pool was cotransfected into COS-7 cells with plasmid pcDNAI/ Amp-A2, containing the HLA-A2.1 gene. Duplicate microcultures were transfected and screened two days later for their ability to stimulate TNF release by CTL 213. The DNA of one of the 640 pools produced in both duplicates a level of TNF that was significantly above the average and this was confirmed in a second transfection experiment. Bacteria of the positive pool were cloned and their plasmid (Fig. 5) . Another amplified sequence extending from nt 47 to 185 proved unable to transfer the expression of NA17-A. W e concluded that the starting point of the sequence coding for the antigenic peptide was located between nt 35 and 47. W e observed that nt 38-67 coded for a decapeptide corresponding to the consensus sequence of the peptides binding to HLA-A2.1 (33) . This peptide, VLPDVFIRCV, was synthesized and incubated with T2 cells, which are HLA-A2 cells with an antigen processing defect resulting in an increased capacity to present exogenous peptides (34, 35) . T2 cells incubated with the peptide were lysed by CTL 213. Nonapeptide V L P D V F I R C sensitized T2 cells equally well, with half-maximum lysis obtained at peptide concentrations of 1 nM, whereas nonapeptide L P D V F I R C V and octapeptide V L P D V F I R failed to confer recognition by the CTL (Fig. 6) .
Antigen N A 17-A Is Encoded by an Intron. The coding sequence of the antigenic peptide was located on c D N A 560 in front o f the region corresponding to the published G n T -V c D N A (Fig. 4) . Accordingly, it seemed that either this sequence belonged to an unrelated c D N A which had been ligated in front of the G n T -V sequence, or it belonged to the G n T -V gene, as part of an alternative exon or an unspliced intron. To explore the second possibility, we set out to isolate the G n T -V gene.
A h gene hbrary prepared with D N A of the M Z 2 -M E L cell line was screened with probe B, corresponding to nt Peptide concentration (nM) Figure 6 . Lysis by CTL 213 ofT2 cells, which express HLA-A2, after incubation with synthetic peptides corresponding to sequences of cDNA 560. Target cells were chromium labeled and incubated for 30 min with the peptides at the concentrations indicated. CTL 213 was then added at an E/T ratio of 10. Chromium release was measured after 4 h.
8.5-kb genomic fragment contained the GnT-V exon (B)
shared with cDNA 560, whereas the 5.5-kb fragment contained the preceding GnT-V exon (A). Partial sequencing of the 8.5-kb fragment (Fig. 7) showed that it contained a sequence identical to exon B and, immediately in front of it, a sequence identical to the initial 84 bp of cDNA 560, which contain the sequence coding for the antigenic peptide. This region ends with a consensus splice acceptor sequence. Downstream of region B, the sequence of the 8.5-kb genomic fragment corresponded neither to that of cDNA 560, nor to that of the GnT-V cDNA. The two first nucleotides of this sequence are GT, as expected for the beginning of an intron.
In the 5.5-kb SacI fragment of the genomic clone ( Fig.  7) we found a sequence identical to the 150 bp sequence of the GnT-V cDNA (positions 1526 to 1675) that immediately precedes region B. This exon (A) is preceded and followed by consensus splice sites.
We conclude that the genomic clone contains two exons (A and B) which are present in the GnT-V cDNA. They are separated by an intron of at least 8 kb (Fig. 4) . The sequence coding for the antigenic peptide is located near the very end of this intron. Its phase is different from that of the large open reading frame which runs through all the GnT-V cDNA.
Characterization of the mRNA Coding for Antigen NA 17-A.
The intron region coding for the antigenic peptide could be available for translation as a result of the presence of incompletely spliced Gnt-V messenger in the cytosol. Alternatively, a normally silent promoter region located in the intron between exons A and B (Fig. 4) could be activated in some melanoma cells to produce an additional messenger species. In the first hypothesis, 5' anchored PCR would be expected to yield long and diverse products corresponding to incomplete cDNA molecules, since the intron is at least 8 kb long. In the second hypothesis, and in so far as the relevant promoter would be located near the end of the intron, complete 5' anchored PCR products could be obtained indicating the new transcription starting point.
Three independent anchored PCR experiments were performed on RNA of melanoma cell line LB24-MEL, which is highly recognized by CTL 213 (Table 1) . The primers are shown in Fig. 7 . In experiment I, reverse transcription (RT) was primed with oligonucleotide YG104, located in the intron. The cDNA was ligated to an anchor oligonucleotide and submitted to two consecutive series of 30 amplification cycles with the anchor complementary primer and as anti-sense primers the reverse transcription primer in the first series of amplification and primer YG20 (Fig. 7) in the second. The three cloned PCR products that were sequenced started at positions -247, -198 and -91 relative to exon B (Fig. 7, vertical arrows) . In experiments II (RT primer YG104, second anti-sense YG31) and III (RT primer VB56, second anti-sense YG20), PCR products with 5' ends scattered between -288 and -96 were identified. These results suggest the existence of an imprecise transcription origin located in the distal part of the intron.
To exclude the possibility of artefactual anchored PCR results due to a secondary structure in the RNA molecule blocking reverse transcription, we cloned in a transcription vector a HindlII-SacI restriction fragment containing exon B and the last 1087 bases of the preceding intron (Fig. 7) . Sense RNA was synthesized in vitro and reverse transcribed with primer YG104. PCR was performed on the cDNA product with anti-sense primer YG20 and sense primer YGl18 which starts at position -588, i.e., 300 nt upstream of the earliest putative transcription starting point identified by anchored PCR. A specific 531-bp band was obtained, indicating that the reverse transcriptase can run across the putative transcription start region.
To identify the 3' end of the messenger containing the peptide coding region, we used an oligo-dT primer for reverse transcription of LB24-MEL RNA. The cDNA was then submitted to two series of PCR amplification cycles with oligo-dT primer and two overlapping sense primers located in the peptide coding region. The sequence of the PCR product was identical to the end of the intron, followed by the complete 3' end (746 bp) of the published GnT-V cDNA. It seems therefore that the antigen coding messenger starts with an unusual transcription site located in an intron but shows no further transcription or splicing difference with the normal messenger. In the antigen-coding messenger, the open reading frame starts 49 bp before exon B and it is interrupted 222 nt later, in the initial part of the putative exon "C" of the GnT-V gene.
Expression of the Normal GnT-V Enzyme. We designed
RT-PCR assays that distinguish the expression of the fully spliced GnT-V transcript (32) from that of the transcript coding for antigen NA17-A. An RT-PCR performed with primers located in exons A and B (Fig. 4; primers a and b) amplifies a 206-bp fragment only from the fully spliced messenger. One sample of each of the large variety of norreal adult tissues appearing in Table 3 
Expression of the Antigen-coding Sequence in Tumors.
An I<T-PCR assay named I-C, performed with a sense primer located near the end of the intron that precedes exon B and an anti-sense primer located downstream exon B in the GnT-V transcript (Fig. 4, primers i and c) , amplifies a 271-bp fragment only from the GnT-V transcript that codes for antigen NA17-A. This assay yielded no amplifi-Guilloux et al.
cation product with genomic DNA, indicating that the intron located between exons B and C is of considerable length.
13 HLA-A2 tumor cell lines were tested with a quantitative version of RT-PCR I-C and also for their ability to stimulate TNF release by CTL 213 ( Table 1 ). The 8 HLA-A2 tumor cell lines that stimulated TNF release by CTL 213 had a level of expression of NA17-A messenger between 300 and 8% of that observed in the MZ2-MEL celt line. There was a good correlation between the level of the NA17-A messenger and the amount of TNF released by the CTL. The five HLA-A2 tumor cell lines that were negative in the TNF assay expressed less than 3% of the amount of NA17-A messenger found in MZ2-MEL cells. 42 melanoma samples and 198 samples of tumors other than melanoma were tested by IkT-PCI< I-C (Table 2) . About half the melanoma samples expressed levels of NA17-A messenger that should lead to antigen expression (More than 12% of that of MZ2-MEL), while tumors of other types did not, with the exception of one brain tumor and one sarcoma.
Expression of the Antigen-coding Sequence in Normal Tissues.
A variety of normal tissue samples were tested by lkT-PCP, I-C for the expression of the RNA coding for antigen NA17-A (Table 3 ). All the 54 samples were negative except for one breast sample (out of six tested) and one brain sample (out of five), which contained substantia nigra. These samples gave signals evaluated to 3 and 4%, respectively, of the level observed in the MZ2-MEL cell line.
Whereas two skin samples were negative in the IkT- PCP, assay, a melanocyte culture was clearly positive. We felt that the expression of the NA17-A messenger might be related to in vitro culture conditions and we reexamined the presence of the messenger in the skin. We evaluated the expression of the NA17-A coding sequence relative to that of the tyrosinase gene which is known to be expressed specifically in melanocytes. We considered that if the NA17-A messenger is produced by normal melanocytes, which constitute a few percent of the cells of the basal layer of the epidermis, the expression of this messenger in the skin sample ought to be decreased relative to that found in the MZ2-MEL melanoma line proportionately to that of the tyrosinase messenger. In the two skin samples that were tested we observed a level of tyrosinase mlLNA averaging 7.5% of that found in MZ2-MEL cells. For the NA17-A coding sequence the average was only 0.45%, suggesting that skin melanocytes do not express a significant level of the sequence coding for antigen NA17-A. 
Discussion
Tumor antigen NA17-A is expressed by approximately 50% of HLA-A2 melanomas. It is a product of the gene that codes for N-acetylglucosaminyltransferase V (GriT-V). This enzyme is located in the Golgi apparatus. It catalyzes the transfer of N-acetylglucosamine in [3(1,6 )-linkage to the et(1,6)-linked mannose of biantennary N-linked oligosaccharides (35a). This enzyme is active in many normal tissues. Its activity in many cell types has been shown to increase significandy after infection by various transforming viruses or transfection with oncogenes, such as ras (36) (37) (38) (39) (40) . For several cell lines, increase in the activity of GnT-V appears to correlate with increase in the metastatic potential (41, 42) .
Remarkably, the region coding for the peptide that binds to HLA-A2.1 to form antigen NA17-A is located in an intron. The results ofanchored-PCR amplification suggest that messengers coding for the antigenic peptide are generated by the activation in melanoma cells of a promoter located in this intron. No consensus TATA box can be found in the rather diffuse region where starting points of 5' anchored-PCR clones were found, and this may account for the absence of a precise transcription starting point. The examination of the putative promoter region did not reveal any transcription factor binding sequence that seemed likely to be responsible for the transcriptional activation in melanoma. We intend to clone this region into a reporter vector, as a first step in analyzing the activation of the putative intron promoter in the melanoma cells.
The AUG codon, which immediately precedes the antigen coding sequence, does not benefit from a favorable upstream sequence for a translation start: instead of the consensus purine, there is a C in position -3. But there is a G in position + 4, which ought to compensate for this.
The decapeptide VLPDVFIRCV, which is recognized in association with the HLA-A2.1 molecule by CTL directed against NA17-A is a consensus HLA-A2.1 binding peptide (33) with anchor residues L and V in positions 2 and 10, respectively. Interestingly, nonapeptide VLPDV-FIRC induces lysis by CTL 213 equally well, even though it lacks the COOH-terminal consensus anchor residue.
The mRNA that codes for the NA17-A peptide could also code for several other HLA-binding peptides that are not encoded by the normal GnT-V mRNA. This is because the AUG located in front of the NA17-A peptide opens a reading frame which is out of phase with the norreal GnT-V coding sequence and which codes for a polypeptide of 74 amino acids. Thus, the abnormal GnT-V messenger could code for several tumor antigens recognized by T lymphocytes.
We examined whether antigen NA17-A is a melanocytic differentiation antigen like those encoded by tyrosinase, Melan-A M~'r-l, gp 100 vr~e~7 and gp75, or whether its expression is restricted to tumors. The messenger coding for antigen NA17-A seemed not to be expressed at a significant level in the skin melanocytes, indicating that antigen NA17-A is not a differentiation antigen. The expression of the NA17-A messenger appears to be tumor-specific, even though most normal tissues produced weak signals after 38 PCR cycles. But these weak signals may result from the amplification of incompletely spliced but otherwise normal GnT-V messenger, which is very unlikely to produce the antigenic peptide since the peptide-coding sequence is located near the end of a very long intron containing multiple stop codons in all reading frames. Even if these weak signals represented the appropriate message, the level of expression would most probably be too low to produce enough peptide for CTL recognition. We conclude that it is very likely that the expression of antigen NA17-A is sufficiently tumor-specific to be a useful target for cancer immunotherapy.
